Peptide Supply review: catalogue, lab reports, shipping (2026)
What Peptide Supply publishes about its catalogue, its lab reports, its shipping and its payment terms, read from peptidesupply.org on September 16, 2026and checked against FDA's warning letter database. A listing is not an endorsement, and we do not verify purity, identity or what is in any individual vial.
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
At a glance
| Status | Open |
|---|---|
| Lab reports | Published on the site Lab reports are published where a reader can open them. Match the lot number on the vial to the report. |
| Ships to | United States |
| Payment | Accepted payment methods are not listed on the pages we read. Confirm at checkout. |
| FDA warning letters | None found in FDA's warning letter database when we searched it on September 16, 2026. |
| Website | peptidesupply.org |
Sponsored links below; we may earn a commission. Details.
Visit Peptide SupplyPlain link. We are not an affiliate of Peptide Supply at this time.
Compounds listed
Products this vendor lists that match a compound we track, read from its own catalogue. Coded or abbreviated product names are not mapped, because that would mean guessing at what is in the vial.
- BPC-157
- Retatrutide
- Tirzepatide
- Tesamorelin
- NAD+
- GHK-Cu
- GLOW blend
- KLOW blend
- CJC-1295
- Ipamorelin
- Selank
- Semax
- MOTS-c
- AOD-9604
- DSIP
- TB-500
- Epitalon
What we found
Peptide Supply is a United States storefront that describes itself as supplying high-purity peptides exclusively for research-use-only applications. Its homepage leads with a 99 percent purity claim, HPLC verification and third-party certificates for every product, and its own disclaimer states the products are not intended for use in humans or animals.
The catalogue read from the site's sitemap on 2026-09-16 runs to roughly 32 products and leans toward the metabolic compounds: retatrutide in five sizes and tirzepatide sit alongside the repair and longevity material. It also lists the GLOW and KLOW blends by name. Free shipping is advertised on orders over $100.
Retatrutide has no approved product anywhere and is an investigational molecule; tirzepatide is an approved prescription drug sold under brand names. A research vendor listing either is outside both routes, and the compounding pathway described in our regulatory blocks is not what is happening here.
What “research use only” means, and the market it sits in
Every vendor in this section sells material labelled for research, laboratory or analytical use and not for human consumption. That label is not a formality and it is not a loophole. It is the seller stating that the product has not been through the approval or compounding systems that govern medicines, and that it is not intended for a person.
The market is under active enforcement. FDA's public warning letter database shows a continuing run of unapproved-new-drug and misbranding letters to peptide sellers: Gram Peptides and Pink Pony Peptides on 31 March 2026, Wholesale Peptide on 17 June 2026, and five on a single day, 24 August 2026, to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners and Tex Peptides. Of the vendors profiled here, one appears in that database: Swiss Chems, letter dated 10 December 2024.
Criminal exposure is real as well. In the Northern District of Indiana, the operators of Paradigm Peptides entered guilty pleas on 10 December 2025 over products sold as SARMs that in fact contained testosterone and over unapproved peptide and hCG products; both were sentenced in July 2026. Separately, payment processors have been withdrawing from this category, which is why so many storefronts route buyers to crypto, Zelle or bank wire rather than a card.
There is a lawful route for several of these compounds, and it is not this one. At its meeting on 23–24 July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV and TB-500 (8–6, one abstention) and MOTS-c (7–5, two abstentions) for the section 503A bulk drug substances list. That vote is advisory: FDA decides, and where compounding proceeds it runs through a licensed prescriber and a licensed pharmacy, not a research storefront.
Sources for this section
- FDA warning letter database (searched 16 September 2026)
- FDA warning letter to Swisschems, 10 December 2024 (MARCS-CMS 695663)
- FDA warning letter to Gram Peptides, 31 March 2026
- FDA warning letter to Peak Performance Peptides, 24 August 2026
- United States v. Matthew Kawa, N.D. Indiana (guilty pleas entered 10 December 2025)
- FDA Pharmacy Compounding Advisory Committee, 2026 meeting materials (meeting of 23–24 July 2026)
Compound profiles carry the regulatory status for each substance, and online peptide therapy covers the prescription route.
Frequently asked questions
Is Peptide Supply legit?
The storefront is live, the catalogue resolves and the site states that every product carries a third-party certificate. It is a research-chemical seller: the material is labelled not for human or animal use, and the company itself says so in its disclaimer.
What do Peptide Supply reviews say?
We do not republish reviews from this market. The record we can check is the catalogue, the published testing claims, the free-shipping threshold and the absence of the company from FDA's warning letter database when searched on 2026-09-16.
Does Peptide Supply have a discount code?
The site advertises free shipping over $100 rather than a published discount code. We do not issue codes for any vendor on this site.
Does Peptide Supply publish certificates of analysis?
The homepage states third-party COAs for every product and HPLC verification. The product page we opened did not surface a lot report inline, so ask for the certificate matching the lot number before relying on the claim.
Why does it list retatrutide and tirzepatide?
Both appear in the catalogue. Retatrutide is investigational with no approved product anywhere; tirzepatide is an approved prescription drug. Neither is lawfully sold to a person as a research chemical, which is the enforcement exposure FDA's recent letters to peptide sellers have centred on.
Want it prescribed instead?
Nothing on this page is a route to a peptide for a person. The lawful route runs through a licensed prescriber and a licensed pharmacy, and for several of these compounds it exists today. Our telehealth section compares programs on prescriber type, pharmacy model, whether labs are required, state coverage and published pricing, and each compound profile states what can lawfully be prescribed or compounded right now.
Where the research stands
Our research digests summarise new studies against their primary sources, and are peptides legal explains the difference between an approved drug, a compounded preparation and a research chemical.